financetom
Business
financetom
/
Business
/
enCore Energy to Sell Uranium Assets in New Mexico and Distribute Consideration Shares to Shareholders
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
enCore Energy to Sell Uranium Assets in New Mexico and Distribute Consideration Shares to Shareholders
Mar 18, 2025 5:40 AM

08:01 AM EDT, 03/18/2025 (MT Newswires) -- enCore Energy (EU.V) said Tuesday that it signed a definitive agreement to sell its uranium assets in New Mexico to Verdera Energy.

Under the terms, Verdera will acquire an enCore subsidiary that holds the Crownpoint, Hosta Butte, Nose Rock, West Largo, and Ambrosia Lake-Treeline uranium projects. enCore will receive 50 million Vedera non-voting preferred shares, 73% of Verdera's issued and outstanding shares on a fully diluted basis.

enCore will also get a 2% net proceeds royalty on uranium and a 2% net smelter returns royalty on other minerals extracted and sold from the properties. Verdure will also make a non-refundable cash payment of US$350,000.

"As enCore pushes forward on its aggressive uranium extraction plans in South Texas, we continue to execute on our stated non-core asset disposition strategy to create additional value for shareholders," said William Sheriff, enCore's executive chairman. "We believe that our New Mexico projects deserve a dedicated focus, which they do not currently receive inside enCore's broader portfolio of producing and near-term producing assets."

After the deal closes, Verdera will pursue a listing on a Canadian stock exchange by Dec. 10, which may be extended to Jan. 31, 2026.

enCore said 15 million consideration shares will convert into shares of the resulting listed company and be retained by enCore. The remaining 35 million consideration shares will convert into common shares of the resulting issuer in connection with enCore's planned distribution of shares to its shareholders by way of a stock dividend or similar distribution.

enCore's share price closed 6.2% higher on Monday to $2.23 on the TSXV.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AMC tops revenue target as box office hits drive strong demand
AMC tops revenue target as box office hits drive strong demand
Feb 25, 2025
Feb 25 (Reuters) - AMC Entertainment ( AMC ) topped Wall Street estimates for quarterly revenue on Tuesday, boosted by wildly popular releases including Moana 2 and Wicked that helped draw a strong crowd of moviegoers. Shares of the company rose about 3% in extended trading after it reported a 20% jump in attendance in theaters in the fourth quarter....
Vaxcyte 2024 Loss Narrows
Vaxcyte 2024 Loss Narrows
Feb 25, 2025
05:20 PM EST, 02/25/2025 (MT Newswires) -- Vaxcyte ( PCVX ) reported a full-year 2024 net loss late Tuesday of $3.80 per diluted share, narrower than a per-share loss of $4.14 a year earlier. Analysts polled by FactSet expected a per-share loss of $3.91. The company said it had cash, cash equivalents and investments of $3.13 billion as of Dec....
Range Resources Q4 Adjusted Earnings Rise, Revenue Declines
Range Resources Q4 Adjusted Earnings Rise, Revenue Declines
Feb 25, 2025
05:15 PM EST, 02/25/2025 (MT Newswires) -- Range Resources ( RRC ) late Tuesday reported Q4 adjusted net income of $0.68 per diluted share, up from $0.63 a year earlier. Analysts polled by FactSet expected $0.61. Revenue for the quarter ended Dec. 31 was $626.4 million, down from $941.5 million a year earlier. Analysts surveyed by FactSet expected $691.1 million....
Boehringer Ingelheim wins trial in two Zantac lawsuits
Boehringer Ingelheim wins trial in two Zantac lawsuits
Feb 25, 2025
Feb 25 (Reuters) - Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused cancer, both of which had previously ended with hung juries. A state court jury in Chicago on Monday found in favor of the privately held German drugmaker following a joint trial of individual cases brought by Chicago residents...
Copyright 2023-2026 - www.financetom.com All Rights Reserved